Year: 2025

5-Amino-1-methylquinolinium, commonly referred to as 5-Amino-1MQ, is a small-molecule compound that has recently attracted attention in both the metabolic health and performance enhancement worlds. Originally investigated for its potential to combat obesity, metabolic syndrome, and age-related decline, this NNMT (nicotinamide N-methyltransferase) inhibitor has shown promise in boosting fat metabolism, preserving lean muscle mass, and increasing energy […]

Efinopegdutide (MK‑6024) is a dual GLP‑1/glucagon receptor agonist under investigation for treating metabolic-associated fatty liver disease (MAFLD) and related metabolic disorders. Developed by Merck, this synthetic, PEGylated peptide is engineered to improve liver fat reduction, glucose control, and cardiometabolic health. While GLP‑1 agonists like semaglutide and liraglutide have transformed the treatment of obesity and type 2 […]